Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia

Blood Coagulation and Fibrinolysis

Volumn 22, Issue 1, 2011, Pages 76-78

  Pistulli, Rudin ^a   Oberle, Volker ^b   Figulla, Hans Reiner ^a   Yilmaz, Atilla ^a   Pfeifer, Rüdiger ^a  

^a Division of Cardiology and Intensive Care Medicine   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

acquired coagulation disorders; antiplatelet agents; thrombosis; venous thrombosis

Indexed keywords

ARGATROBAN; DANAPAROID; ENOXAPARIN; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTIGEN ANTIBODY REACTION; ARTICLE; CASE REPORT; CONTINUOUS INFUSION; CROSS REACTION; DRUG WITHDRAWAL; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERTRANSAMINASEMIA; IN VITRO STUDY; MALE; PRIORITY JOURNAL; SINGLE DRUG DOSE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES; ANTICOAGULANTS; CROSS REACTIONS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; POLYSACCHARIDES; THROMBOCYTOPENIA;

EID: 78650793759     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328340ff24     Document Type: Article

References (11)

1. Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 2009; 135:1651-1664.
2. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: Mechanism of interaction of the heparin-dependent antibody with platelets. Br J Haematol 1989; 73:235-240.
3. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1:1471-1478.
4. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006; 40:1383-1387.
5. Greinacher A, Gopinadhan M, Günther JU, Omer-Adam MA, Strobel U, Warkentin TE, et al. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006; 26:2386-2393.
6. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356:2653-2655.
7. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007; 356:2653-2655.
8. Rota E, Bazzan M, Fantino G. Fondaparinux-related thrombocytopenia in a previous low-molecular weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost 2008; 99:779-781.
9. Alsaleh KA, Al-Nasser SMA, Bates SM, Patel A, Warkentin TE, Arnold DM. Delayed-onset HIT caused by low-molecular weight heparin manifesting during fondaparinux prophylaxis. Am J Hematol 2008; 83:876-878.
10. Ratuapli SK, Bobba B, Zafar H. Heparin-induced thrombocytopenia in a patient treated with fondaparinux. Clin Adv Hematol Oncol 2010; 8:61-65.
11. Greinacher A, Amiral J, Dummel V, Vissac A, Kiefel V, Mueller-Eckhardt C. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion 1994; 34:381-385.